FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
Time-Dependent Efficacy of Lymphaticovenous Anastomosis in Secondary Lymphedema: A Rabbit Model Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Ping, Liu Wenzhao, Liu Mingqiang, Yang Jintao, Li Sen, Li Xun
Аннотация
Secondary lymphedema remains a common complication after oncologic lymph node dissection. The optimal timing of lymphaticovenous anastomosis (LVA) is unclear due to a lack of time-dependent large-animal models. Twenty-five New Zealand White rabbits underwent popliteal-region surgery to induce secondary hind limb lymphedema. Animals received immediate LVA (n = 5) or delayed LVA at 4, 8, or 12 weeks after model induction (n = 5 per group); untreated lymphedema controls were included (n = 5). Outcomes included limb circumference/swelling rate, anastomotic patency by indocyanine green (ICG) fluorescence imaging, and histopathology/molecular markers (e.g., VEGF-C, LYVE-1). The model produced sustained hind limb swelling and molecular evidence of lymphangiogenic remodeling (e.g., increased VEGF-C and LYVE-1). Immediate LVA achieved 100% technical success with durable patency during follow-up. Delayed LVA groups demonstrated patency rates of approximately 75%-80%. Immediate intervention resulted in the greatest long-term reduction in swelling compared with delayed interventions. Mean lymphatic and venous diameters were approximately 0.6 and 0.8 mm, respectively, and mean operative time was ~55 min. This rabbit model provides a reproducible platform to evaluate time-dependent LVA efficacy. Earlier intervention yielded superior functional outcomes, while delayed LVA remained feasible and maintained reasonable patency, supporting a clinically relevant therapeutic window.